Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants

References

• Murphy K, Travers P, Walport M. Janeway’s Immunobiology (7th Edition). Garland Science, NY, USA (2007).
   Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol.54(Pt 1), 1–13 (1989).
   PubMedGoogle Scholar
• Matzinger P. The danger model: a renewed sense of self. Science296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest.109(12), 1519–1526 (2002).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Matzinger P, Seder RA, Paul WE, Schwartz RH. Activation events during thymic selection. J. Exp. Med.175(3), 731–742 (1992).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Schwartz RH. CD4+ and CD8+ T cells acquire specific lymphokine secretion potentials during thymic maturation. Nature353(6339), 68–71 (1991).
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Lin BT, Hardy RR. Murine thymic CD4+ T cell subsets: a subset (Thy0) that secretes diverse cytokines and overexpresses the Vβ8 T cell receptor gene family. J. Exp. Med.176(1), 269–274 (1992).
   PubMed Web of Science ®Google Scholar
• Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. An invariant Vα24-JαQ/Vβ11 T cell receptor is expressed in all individuals by clonally expanded CD4–8- T cells. J. Exp. Med.180(3), 1171–1176 (1994).
   PubMed Web of Science ®Google Scholar
• Porcelli S, Yockey CE, Brenner MB, Balk SP. Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4–8- αβ T cells demonstrates preferential use of several Vβ genes and an invariant TCRα chain. J. Exp. Med.178(1), 1–16 (1993).
   PubMed Web of Science ®Google Scholar
• Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what’s in a name? Nat. Rev. Immunol.4(3), 231–237 (2004).
   PubMed Web of Science ®Google Scholar
• Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity16(4), 583–594 (2002).
   PubMed Web of Science ®Google Scholar
• Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med.202(12), 1627–1633 (2005).
   PubMed Web of Science ®Google Scholar
• Duthie MS, Kahn M, White M, Kapur RP, Kahn SJ. Critical proinflammatory and anti-inflammatory functions of different subsets of CD1d-restricted natural killer T cells during Trypanosoma cruzi infection. Infect. Immun.73(1), 181–192 (2005).
   PubMed Web of Science ®Google Scholar
• Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J. Exp. Med.199(7), 947–957 (2004).
   PubMed Web of Science ®Google Scholar
• Zajonc DM, Maricic I, Wu D et al. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med.202(11), 1517–1526 (2005).
   PubMed Web of Science ®Google Scholar
• Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol.26, 877–900 (2005).
   Google Scholar
• Arase H, Arase N, Saito T. Interferon γ production by natural killer (NK) cells and NK1.1+ T cells upon NKR-P1 cross-linking. J. Exp. Med.183(5), 2391–2396 (1996).
   PubMed Web of Science ®Google Scholar
• Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med.195(5), 625–636 (2002).
   PubMed Web of Science ®Google Scholar
• Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol.3(10), 781–790 (2003).
   PubMed Web of Science ®Google Scholar
• Brigl M, Brenner MB. CD1: antigen presentation and T cell function. Annu. Rev. Immunol.22, 817–890 (2004).
   PubMed Web of Science ®Google Scholar
• Vincent MS, Gumperz JE, Brenner MB. Understanding the function of CD1-restricted T cells. Nat. Immunol.4(6), 517–523 (2003).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol.15, 535–562 (1997).
   PubMed Web of Science ®Google Scholar
• Thedrez A, de Lalla C, Allain S et al. CD4 engagement by CD1d potentiates activation of CD4+ invariant NKT cells. Blood110(1), 251–258 (2007).
   PubMed Web of Science ®Google Scholar
• Chen X, Wang X, Besra GS, Gumperz JE. Modulation of CD1d-restricted NKT cell responses by CD4. J. Leuk. Biol.82(6), 1455–1465 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human Vα24 natural killer T cells. J. Exp. Med.195(5), 637–641 (2002).
   PubMed Web of Science ®Google Scholar
• Crowe NY, Coquet JM, Berzins SP et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J. Exp. Med.202(9), 1279–1288 (2005).
   PubMed Web of Science ®Google Scholar
• Porcelli SA, Modlin RL. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol.17, 297–329 (1999).
   PubMed Web of Science ®Google Scholar
• Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A. TAP-independent, β2-microglobulin-dependent surface expression of functional mouse CD1.1. J. Exp. Med.182(6), 1913–1919 (1995).
   PubMed Web of Science ®Google Scholar
• Wu D, Zajonc DM, Fujio M et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc. Natl Acad. Sci. USA103(11), 3972–3977 (2006).
   PubMed Web of Science ®Google Scholar
• Zajonc DM, Cantu C 3rd, Mattner J et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol.6(8), 810–818 (2005).
   PubMed Web of Science ®Google Scholar
• Koch M, Stronge VS, Shepherd D et al. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol.6(8), 819–826 (2005).
   PubMed Web of Science ®Google Scholar
• Silk JD, Salio M, Brown J, Jones EY, Cerundolo V. Structural and functional aspects of lipid binding by CD1 molecules. Annu. Rev. Cell. Dev. Biol.24, 369–395 (2008).
   PubMed Web of Science ®Google Scholar
• Mandal M, Chen XR, Alegre ML et al. Tissue distribution, regulation and intracellular localization of murine CD1 molecules. Mol. Immunol.35(9), 525–536 (1998).
   PubMed Web of Science ®Google Scholar
• Brossay L, Jullien D, Cardell S et al. Mouse CD1 is mainly expressed on hemopoietic-derived cells. J. Immunol.159(3), 1216–1224 (1997).
   PubMed Web of Science ®Google Scholar
• Roark JH, Park SH, Jayawardena J, Kavita U, Shannon M, Bendelac A. CD1.1 expression by mouse antigen-presenting cells and marginal zone B cells. J. Immunol.160(7), 3121–3127 (1998).
   PubMed Web of Science ®Google Scholar
• Bendelac A. Positive selection of mouse NK1+ T cells by CD1-expressing cortical thymocytes. J. Exp. Med.182(6), 2091–2096 (1995).
   PubMed Web of Science ®Google Scholar
• Geissmann F, Cameron TO, Sidobre S et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol.3(4), 650–661 (2005).
   Web of Science ®Google Scholar
• Blumberg RS, Terhorst C, Bleicher P et al. Expression of a nonpolymorphic MHC class I-like molecule, CD1D, by human intestinal epithelial cells. J. Immunol.147(8), 2518–2524 (1991).
   PubMed Web of Science ®Google Scholar
• Larsson LC, Anderson P, Widner H, Korsgrent O. Enhanced survival of porcine neural xenografts in mice lacking CD1d1, but no effect of NK1.1 depletion. Cell Transplant.10(3), 295–304 (2001).
   Web of Science ®Google Scholar
• Karadimitris A, Gadola S, Altamirano M et al. Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc. Natl Acad. Sci. USA98(6), 2950–2952 (2001).
   PubMed Web of Science ®Google Scholar
• Emoto M, Kaufmann SH. Liver NKT cells: an account of heterogeneity. Trends Immunol.24(7), 364–369 (2003).
   PubMed Web of Science ®Google Scholar
• Sandberg JK, Bhardwaj N, Nixon DF. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Vα24 NKT cell compartment. Eur. J. Immunol.33(3), 588–596 (2003).
   PubMed Web of Science ®Google Scholar
• Motsinger A, Haas DW, Stanic AK, Van Kaer L, Joyce S, Unutmaz D. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J. Exp. Med.195(7), 869–879 (2002).
   PubMed Web of Science ®Google Scholar
• Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res.7(10–11), 529–534 (1995).
   PubMed Web of Science ®Google Scholar
• Kawano T, Cui J, Koezuka Y et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science278(5343), 1626–1629 (1997).
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Vα14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol.21, 483–513 (2003).
   PubMed Web of Science ®Google Scholar
• Borg NA, Wun KS, Kjer-Nielsen L et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature448(7149), 44–49 (2007).
   PubMed Web of Science ®Google Scholar
• Sidobre S, Naidenko OV, Sim BC, Gascoigne NR, Garcia KC, Kronenberg M. The Vα14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J. Immunol.169(3), 1340–1348 (2002).
   PubMed Web of Science ®Google Scholar
• Cantu C, Benlagha K, Savage PB, Bendelac A, Teyton L. The paradox of immune molecular recognition of α-galactosylceramide: low affinity, low specificity for CD1d, high affinity for αβ TCRs. J. Immunol.170(9), 4673–4682 (2003).
   PubMed Web of Science ®Google Scholar
• Mattner J, DeBord KL, Ismail N et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature434(7032), 525–529 (2005).
   PubMed Web of Science ®Google Scholar
• Kinjo Y, Wu DY, Kim G et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature434(7032), 520–525 (2005).
   PubMed Web of Science ®Google Scholar
• Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur. J. Immunol.35(6), 1692–1701 (2005).
   PubMed Web of Science ®Google Scholar
• Dieckmann R, Graeber I, Kaesler I, Szewzyk U, von Dohren H. Rapid screening and dereplication of bacterial isolates from marine sponges of the Sula Ridge by intact-cell-MALDI-TOF mass spectrometry (ICM-MS). Appl. Microbiol. Biotechnol.67(4), 539–548 (2005).
   PubMed Web of Science ®Google Scholar
• Tupin E, Kinjo T, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol.5(6), 405–417 (2007).
   PubMed Web of Science ®Google Scholar
• Kinjo Y, Tupin E, Wu D et al. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol.7(9), 978–986 (2006).
   PubMed Web of Science ®Google Scholar
• Belperron AA, Dailey CM, Bockenstedt LK. Infection-induced marginal zone B cell production of Borrelia hermsii-specific antibody is impaired in the absence of CD1d. J. Immunol.174(9), 5681–5686 (2005).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+ T lymphocytes. Science268(5212), 863–865 (1995).
   PubMed Web of Science ®Google Scholar
• Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Vα24+ CD4-CD8- T cells. J. Exp. Med.186(1), 109–120 (1997).
   PubMed Web of Science ®Google Scholar
• Park SH, Roark JH, Bendelac A. Tissue-specific recognition of mouse CD1 molecules. J. Immunol.160(7), 3128–3134 (1998).
   PubMed Web of Science ®Google Scholar
• Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat. Immunol.4(12), 1230–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Benlagha K, Kyin T, Beavis A, Teyton L, Bendelac A. A thymic precursor to the NK T cell lineage. Science296(5567), 553–555 (2002).
   PubMed Web of Science ®Google Scholar
• Zimmer MI, Colmone A, Felio K, Xu H, Ma A, Wang CR. A cell-type specific CD1d expression program modulates invariant NKT cell development and function. J. Immunol.176(3), 1421–1430 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou D, Mattner J, Cantu C et al. Lysosomal glycosphingolipid recognition by NKT cells. Science306(5702), 1786–1789 (2004).
   PubMed Web of Science ®Google Scholar
• Xia C, Yao Q, Schumann J et al. Synthesis and biological evaluation of α-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3). Bioorg. Med. Chem. Lett.16(8), 2195–2199 (2006).
   PubMed Web of Science ®Google Scholar
• Porubsky S, Speak AO, Luckow B, Cerundolo V, Platt FM, Grone HJ. Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl Acad. Sci. USA104(14), 5977–5982 (2007).
   PubMed Web of Science ®Google Scholar
• Christiansen D, Milland J, Mouhtouris E et al. Humans lack iGb3 due to the absence of functional iGb3-synthase: implications for NKT cell development and transplantation. PLoS Biol.6(7), e172 (2008).
   PubMed Web of Science ®Google Scholar
• Speak AO, Salio M, Neville DC et al. Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl Acad. Sci. USA104(14), 5971–5976 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y, Teneberg S, Thapa P, Bendelac A, Levery SB, Zhou D. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology18(2), 158–165 (2008).
   PubMed Web of Science ®Google Scholar
• Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: innate B and T lymphocytes. Nat. Rev. Immunol.1(3), 177–186 (2001).
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest.114(10), 1379–1388 (2004).
   PubMed Web of Science ®Google Scholar
• Van Kaer L. Regulation of immune responses by CD1d-restricted natural killer T cells. Immunol. Res.30(2), 139–153 (2004).
   PubMed Web of Science ®Google Scholar
• Coquet JM, Chakravarti S, Kyparissoudis K et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc. Natl Acad. Sci. USA105(32), 11287–11292 (2008).
   PubMed Web of Science ®Google Scholar
• Matsuda JL, Gapin L, Baron JL et al. Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl Acad. Sci. USA100(14), 8395–8400 (2003).
   PubMed Web of Science ®Google Scholar
• Stetson DB, Mohrs M, Reinhardt RL et al. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J. Exp. Med.198(7), 1069–1076 (2003).
   PubMed Web of Science ®Google Scholar
• Parekh VV, Lalani S, Van Kaer L. The in vivo response of invariant natural killer T cells to glycolipid antigens. Int. Rev. Immunol.26(1–2), 31–48 (2006).
   Web of Science ®Google Scholar
• Parekh VV, Singh AK, Wilson MT et al. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct α- and β-anomeric glycolipids. J. Immunol.173(6), 3693–3706 (2004).
   PubMed Web of Science ®Google Scholar
• Nishimura T, Kitamura H, Iwakabe K et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol.12(7), 987–994 (2000).
   PubMed Web of Science ®Google Scholar
• Kitamura H, Ohta A, Sekimoto M et al. α-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell. Immunol.199(1), 37–42 (2000).
   PubMed Web of Science ®Google Scholar
• Carnaud C, Lee D, Donnars O et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol.163(9), 4647–4650 (1999).
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Hemmi H, Steinman RM. Innate Vα14+ natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol. Rev.220, 183–198 (2007).
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med.198(2), 267–279 (2003).
   PubMed Web of Science ®Google Scholar
• Kitamura H, Iwakabe K, Yahata T et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J. Exp. Med.189(7), 1121–1128 (1999).
   PubMed Web of Science ®Google Scholar
• Van Kaer L. α-galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol.5(1), 31–42 (2005).
   PubMed Web of Science ®Google Scholar
• Goff RD, Gao Y, Mattner J et al. Effects of lipid chain lengths in α-galactosylceramides on cytokine release by natural killer T cells. J. Am. Chem. Soc.126(42), 13602–13603 (2004).
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature413(6855), 531–534 (2001).
   PubMed Web of Science ®Google Scholar
• Yu KO, Im JS, Molano A et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides. Proc. Natl Acad. Sci. USA102(9), 3383–3388 (2005).
   PubMed Web of Science ®Google Scholar
• Fujio M, Wu D, Garcia-Navarro R, Ho DD, Tsuji M, Wong CH. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J. Am. Chem. Soc.128(28), 9022–9023 (2006).
   PubMed Web of Science ®Google Scholar
• Yang G, Schmieg J, Tsuji M, Franck RW. The C-glycoside analogue of the immunostimulant α-galactosylceramide (KRN7000): synthesis and striking enhancement of activity. Angew. Chem. Int. Ed. Engl.43(29), 3818–3822 (2004).
   PubMed Web of Science ®Google Scholar
• Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand α-galactosylceramide. J. Exp. Med.198(11), 1631–1641 (2003).
   PubMed Web of Science ®Google Scholar
• Harada M, Seino KI, Wakao H et al. Down-regulation of the invariant Vα14 antigen receptor in NKT cells upon activation. Int. Immunol.16(2), 241–247 (2004).
   PubMed Web of Science ®Google Scholar
• Crowe NY, Uldrich AP, Kyparissoudis K et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NKT cells. J. Immunol.171(8), 4020–4027 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson MT, Johansson C, Olivares-Villagomez D et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl Acad. Sci. USA100(19), 10913–10918 (2003).
   PubMed Web of Science ®Google Scholar
• Eberl G, MacDonald HR. Rapid death and regeneration of NKT cells in anti-CD3ε- or IL-12-treated mice: a major role for bone marrow in NKT cell homeostasis. Immunity9(3), 345–353 (1998).
   PubMed Web of Science ®Google Scholar
• Parekh VV, Wilson MT, Olivares-Villagomez D et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J. Clin. Invest.115(9), 2572–2583 (2005).
   PubMed Web of Science ®Google Scholar
• Van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol.19(3), 354–364 (2007).
   PubMed Web of Science ®Google Scholar
• Van Kaer L, Joyce S. Innate immunity: NKT cells in the spotlight. Curr. Biol.15(11), R429–R431 (2005).
   Web of Science ®Google Scholar
• Kim S, Lalani S, Parekh VV, Vincent TL, Wu L, Van Kaer L. Impact of bacteria on the phenotype, functions and therapeutic activities of iNKT cells in mice. J. Clin. Invest.118(6), 2301–2315 (2008).
   PubMed Web of Science ®Google Scholar
• Lin Y, Roberts TJ, Wang CR, Cho S, Brutkiewicz RR. Long-term loss of canonical NKT cells following an acute virus infection. Eur. J. Immunol.35(3), 879–889 (2005).
   PubMed Web of Science ®Google Scholar
• Snyder-Cappione JE, Nixon DF, Loo CP et al. Individuals with pulmonary tuberculosis have lower levels of circulating CD1d-restricted NKT cells. J. Infect. Dis.195(9), 1361–1364 (2007).
   PubMed Web of Science ®Google Scholar
• Ulrich AP, Crowe NY, Kyparissoudis K et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, BIM-dependent contraction, and hyporesponsiveness to further antigenic challenge. J. Immunol.175(5), 3092–3101 (2005).
   PubMed Web of Science ®Google Scholar
• Ikarashi Y, Iizuka A, Koshidaka Y et al. Phenotypical and functional alterations during the expansion phase of invariant Vα14 natural killer T (Vα14i NKT) cells in mice primed with α-galactosylceramide. Immunology116(1), 30–37 (2005).
   PubMedGoogle Scholar
• Giaccone G, Punt CJA, Ando Y et al. A Phase I study of natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer. Res.8(12), 3702–3709 (2002).
   PubMed Web of Science ®Google Scholar
• Chiba A, Dascher CC, Besra GS, Brenner MB. Rapid NKT cell responses are self-terminating during the course of microbial infection. J. Immunol.181(4), 2292–2302 (2008).
   PubMed Web of Science ®Google Scholar
• Choi HJ, Xu H, Geng Y, Colmone A, Cho H, Wang CR. Bacterial infection alters the kinetics and function of iNKT cell responses. J. Leuk. Biol.84 DOI: 10.1189/jlb.0108038 (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Halder RC, Aguilera C, Maricic I, Kumar V. Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Invest.117(8), 2302–2312 (2007).
   PubMed Web of Science ®Google Scholar
• Yanagisawa K, Exley MA, Jiang X, Ohkochi N, Taniguchi M, Seino K. Hyporesponsiveness to natural killer T-cell ligand α-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Cancer Res.66(23), 11441–11446 (2006).
   PubMed Web of Science ®Google Scholar
• Tahir SM, Cheng O, Shaulov A et al. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol.167(7), 4046–4050 (2001).
   PubMed Web of Science ®Google Scholar
• Stober D, Jomantaite I, Schirmbeck R, Reimann J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol.170(5), 2540–2548 (2003).
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol.171(10), 5140–5147 (2003).
   PubMed Web of Science ®Google Scholar
• Ko SY, Lee KA, Youn HJ et al. Mediastinal lymph node CD8α- DC initiate antigen presentation following intranasal coadministration of α-GalCer. Eur. J. Immunol.37(8), 2127–2137 (2007).
   PubMed Web of Science ®Google Scholar
• Silk JD, Hermans IF, Gileadi U et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest.114(12), 1800–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med.199(12), 1607–1618 (2004).
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Hemmi H et al. Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc. Natl Acad. Sci. USA103, 11252–11257 (2006).
   PubMed Web of Science ®Google Scholar
• Taraban VY, Martin S, Attfield KE et al. Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J. Immunol.180(7), 4615–4620 (2008).
   PubMed Web of Science ®Google Scholar
• Singh N, Hong S, Scherer DC et al. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol.163(5), 2373–2377 (1999).
   PubMed Web of Science ®Google Scholar
• Burdin N, Brossay L, Kronenberg M. Immunization with α-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur. J. Immunol.29(6), 2014–2025 (1999).
   PubMed Web of Science ®Google Scholar
• Galli G, Nuti S, Tavarini S et al. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J. Exp. Med.197(8), 1051–1057 (2003).
   PubMed Web of Science ®Google Scholar
• Galli G, Pittoni P, Tonti E et al. Invariant NKT cells sustain specific B cell responses and memory. Proc. Natl Acad. Sci. USA104(10), 3984–3989 (2007).
   PubMed Web of Science ®Google Scholar
• Devera TS, Shah HB, Lang GA, Lang ML. Glycolipid-activated NKT cells support the induction of persistent plasma cell responses and antibody titers. Eur. J. Immunol.38(4), 1001–1011 (2008).
   PubMed Web of Science ®Google Scholar
• Kim JO, Kim DH, Chang WS et al. Asthma is induced by intranasal coadministration of allergen and natural killer T-cell ligand in a mouse model. J. Allergy Clin. Immunol.114(6), 1332–1338 (2004).
   PubMed Web of Science ®Google Scholar
• Campos RA, Szczepanik M, Itakura A et al. Cutaneous immunization rapidly activates liver invariant Vα14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact hypersensitivity. J. Exp. Med.198(12), 1785–1796 (2003).
   PubMed Web of Science ®Google Scholar
• Campos RA, Szczepanik M, Lisbonne M, Itakura A, Leite-de-Moraes M, Askenase PW. Invariant NKT cells rapidly activated via immunization with diverse contact antigens collaborate in vitro with B-1 cells to initiate contact sensitivity. J. Immunol.177(6), 3686–3694 (2006).
   PubMed Web of Science ®Google Scholar
• Rajewsky K. Clonal selection and learning in the antibody system. Nature381(6585), 751–758 (1996).
   PubMed Web of Science ®Google Scholar
• Lang GA, Exley MA, Lang ML. The CD1d-binding glycolipid α-galactosylceramide enhances humoral immunity to T-dependent and T-independent antigen in a CD1d-dependent manner. Immunology119(1), 116–125 (2006).
   PubMed Web of Science ®Google Scholar
• Lang GA, Devera TS, Lang ML. Requirement for CD1d expression by B cells to stimulate NKT cell-enhanced antibody production. Blood111(4), 2158–2162 (2008).
   PubMed Web of Science ®Google Scholar
• Barral P, Eckl-Dorna J, Harwood NE et al. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc. Natl Acad. Sci. USA105(24), 8345–8350 (2008).
   PubMed Web of Science ®Google Scholar
• Leadbetter EA, Brigl M, Illarionov P et al. NK T cells provide lipid antigen-specific cognate help for B cells. Proc. Natl Acad. Sci. USA105(24), 8339–8344 (2008).
   PubMed Web of Science ®Google Scholar
• Gray JD, Horwitz DA. Activated human NK cells can stimulate resting B cells to secrete immunoglobulin. J. Immunol.154(11), 5656–5664 (1995).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med.195(5), 617–624 (2002).
   PubMed Web of Science ®Google Scholar
• Schmieg J, Gonzalez-Aseguinolaza G, Tsuji M. The role of natural killer T cells and other T cell subsets against infection by the pre-erythrocytic stages of malaria parasites. Microbes Infect.5(6), 499–506 (2003).
   PubMed Web of Science ®Google Scholar
• Ko SY, Ko HJ, Chang WS, Park SH, Kweon MN, Kang CY. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol.175(5), 3309–3317 (2005).
   PubMed Web of Science ®Google Scholar
• Kamijuku H, Nagata Y, Jiang X et al. Mechanism of NKT cell activation by intranasal coadministration of α-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol.1(3), 208–218 (2008).
   PubMed Web of Science ®Google Scholar
• Youn HJ, Ko SY, Lee KA et al. A single intranasal immunization with inactivated influenza virus and α-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine25(28), 5189–5198 (2007).
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen A, Li X et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine26(15), 1807–1816 (2008).
   PubMed Web of Science ®Google Scholar
• Seino K, Motohashi S, Fujisawa T, Nakayama T, Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci.97(9), 807–812 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa A, Motohashi S, Ishikawa E et al. A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res.11(5), 1910–1917 (2005).
   PubMed Web of Science ®Google Scholar
• Nieda M, Okai M, Tazbirkova A et al. Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood103(2), 383–389 (2004).
   PubMed Web of Science ®Google Scholar
• Chang DH, Osman K, Connolly J et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosylceramide loaded mature dendritic cells in cancer patients. J. Exp. Med.201(9), 1503–1517 (2005).
   PubMed Web of Science ®Google Scholar
• Fujii S. Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies. Trends Immunol.29(5), 242–249 (2008).
   PubMed Web of Science ®Google Scholar
• Liu K, Idoyaga J, Charalambous A et al. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med.202(11), 1507–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Cross-presentation of glycolipid from tumor cells loaded with α-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J. Exp. Med.204(11), 2641–2653 (2007).
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-γ-producing NKT response induced with α-galactosylceramide-loaded DCs. Nat. Immunol.3(9), 867–874 (2002).
   PubMed Web of Science ®Google Scholar
• Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells loaded with α-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J. Immunol.178(5), 2853–2861 (2007).
   PubMed Web of Science ®Google Scholar
• Silk JD, Salio M, Reddy BG et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J. Immunol.180(10), 6452–6456 (2008).
   PubMed Web of Science ®Google Scholar
• Mattner J, Savage PB, Leung P et al. Liver autoimmunity triggered by NKT cells. Cell Host Microbe3(5), 304–315 (2008).
   PubMed Web of Science ®Google Scholar
• Wilson MT, Van Kaer L. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases. Curr. Pharm. Des.9(3), 201–220 (2003).
   PubMed Web of Science ®Google Scholar
• Nieda M, Nicol A, Koezuka Y et al. Activation of human Vα24 NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24 TCR-mediated manner. Hum. Immunol.60(1), 10–19 (1999).
   PubMed Web of Science ®Google Scholar
• Billiau A, Matthys P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leuk. Biol.70(6), 849–860 (2001).
   PubMed Web of Science ®Google Scholar
• Veldt BJ, van der Vliet HJ, von Blomberg BM et al. Randomized placebo controlled Phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C. J. Hepatol.47(3), 356–365 (2007).
   PubMed Web of Science ®Google Scholar